Erythromycin A dihydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Erythromycin A dihydrate 

Erythromycin A dihydrate 是由放线菌产生的大环内酯类抗生素 (antibiotic)，具有广泛的抗菌活性。Erythromycin A dihydrate 通过结合细菌的 50S 核糖体亚基而起作用，并通过阻断转肽和/或易位反应来抑制 RNA 依赖性蛋白 (RNA-dependent protein synthesis) 的合成，而不会影响核酸的合成。Erythromycin A dihydrate 在不同领域的研究中显示出抗肿瘤特性和保护神经的作用。

Erythromycin A dihydrate

Erythromycin A dihydrate Chemical Structure

CAS No. : 59319-72-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Erythromycin A dihydrate 的其他形式现货产品:

Erythromycin

生物活性

Erythromycin A dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research[3][4].

IC50 & Target

Bacterial; RNA-dependent protein synthesis[1]
体外研究
(In Vitro)

Erythromycin A dihydrate inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1].
Erythromycin A dihydrate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line: Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat)
Concentration: 10, 100 μM
Incubation Time: 24, 72 hours
Result: Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD).

体内研究
(In Vivo)

Erythromycin A dihydrate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice[3].
Erythromycin A dihydrate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3].
Erythromycin A dihydrate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 cells[3]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: Gastric intubation; 30-120 days
Result: Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.
Animal Model: Male Sprague-Dawley rats (8-week-old, 250-300 g)[4]
Dosage: 50 mg/kg
Administration: Subcutaneous single injection
Result: Reduced infarct volume and edema volume, improved neurological deficit.

Clinical Trial

分子量

769.96

Formula

C37H71NO15
CAS 号

59319-72-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.

    [2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.

    [3]. K Hamada, et al. Antitumor Effect of Erythromycin in Mice. Chemotherapy

    [4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务